<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680833</url>
  </required_header>
  <id_info>
    <org_study_id>RegionSkaneKKLund2</org_study_id>
    <nct_id>NCT03680833</nct_id>
  </id_info>
  <brief_title>Sentinel Node Detection in Cervical Cancer</brief_title>
  <acronym>SLNcxca</acronym>
  <official_title>Sentinel Node Detection in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of sensitivity of Sentinel lymph nodes for detecting nodal metastases in cervical&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive women with stage 1a2-2a1 cervical cancer scheduled for surgery will be approached&#xD;
      for eligibility by defined criteria.&#xD;
&#xD;
      Sentinel nodes will be detected by a combined use of Indocyanine green and Tc99 radiocolloid&#xD;
      ( first 75 patients) and for the continuation with either the combined use or the best&#xD;
      performing of those tracers.&#xD;
&#xD;
      Technical success rates, adverse events (related study intervention and overall) sensitivity&#xD;
      and negative predictive values will be estimated.&#xD;
&#xD;
      An interim analyse will be performed after 34 node positive patients based on the Fleming two&#xD;
      stage analyse. The null hypothesis of sensitivity of 85% will be tested against an estimated&#xD;
      sensitivity of 95%. At this stage the study may be closed for futility, closed as hull&#xD;
      hypothesis is rejected or continued to reach another 28 node positive patients.&#xD;
&#xD;
      As a full pelvic lymphadenectomy will be performed after detection of sentinel nodes patient&#xD;
      will act ast their own controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective cohort study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sentinel node detection in cervical cancer; Sensitivity and negative predictive values for identifying pelvic nodal disease, See detailed study protocol</measure>
    <time_frame>4-5 years</time_frame>
    <description>Detection of Sentinel nodes followed by full pelvic lymphadenectomy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Sentinel Lymph Node Biopsy</condition>
  <arm_group>
    <arm_group_label>prospective cohort study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.&#xD;
The intervention is the detection and removal of sentinel lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node detection in cervical cancer</intervention_name>
    <description>The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes</description>
    <arm_group_label>prospective cohort study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women of age 18 years and older at the time of informed consent.&#xD;
&#xD;
          -  Women with a pathologically proven cervical carcinoma of any histologic subtype,&#xD;
             clinically stage 1a2- 2a1 planned for primary surgery&#xD;
&#xD;
          -  Absence of any exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non consenting patients&#xD;
&#xD;
          -  Ongoing pregnancy&#xD;
&#xD;
          -  Inability to understand written and/or oral study information&#xD;
&#xD;
          -  Who performance status III or more&#xD;
&#xD;
          -  Previous lower limb lymphedema&#xD;
&#xD;
          -  Surgical contraindication to a laparoscopic approach or lymphadenectomy at surgeons&#xD;
             discretion.&#xD;
&#xD;
          -  Anesthesiologic contraindication to a laparoscopic approach at the anesthetist's&#xD;
             discretion&#xD;
&#xD;
          -  Locally advanced disease or intraabdominal/distant metastases at preoperative CT, MRI&#xD;
             or ultrasonography&#xD;
&#xD;
          -  Radiologically suspect pelvic nodal metastatic disease according to the RECIST&#xD;
             criteria (&gt;= 1 node with &gt;=16 mm short axis diameter)&#xD;
&#xD;
          -  Allergy to Iodine&#xD;
&#xD;
          -  Patients with a known liver disease&#xD;
&#xD;
          -  Patients with a significant bleeding disorder or mandatory antithrombotic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Persson, ass professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skane</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Persson, ass professor</last_name>
    <phone>+46733522080</phone>
    <email>jan.persson@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linnea Ekdahl, MD</last_name>
    <phone>0739292631</phone>
    <email>linnea.ekdahl@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecology and Obstetrics</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Persson, ass professor</last_name>
      <phone>+46733522080</phone>
      <email>jan.persson@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Linnea Ekdahl, MD</last_name>
      <phone>+46739292631</phone>
      <email>linnea.ekdahl@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03680833/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

